Asset Details
Do you wish to reserve the book?
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Do you wish to request the book?
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development and prognosis of hepatocellular carcinoma in patients with diabetes
2023
Overview
The incidence of diabetes mellitus and hepatocellular carcinoma (HCC) has been increasing worldwide during the last few decades, in the context of an increasing prevalence of obesity and non-alcoholic fatty liver disease (NAFLD). Epidemiologic studies have revealed that patients with diabetes have a 2- to 3-fold increased risk of developing HCC, independent of the severity and cause of the underlying liver disease. A bidirectional relationship exists between diabetes and liver disease: advanced liver disease promotes the onset of diabetes, and HCC is an important cause of death in patients with diabetes; conversely, diabetes is a risk factor for liver fibrosis progression and HCC development, and may worsen the long-term prognosis of patients with HCC. The existence of close interconnections among diabetes, obesity, and NAFLD causes insulin resistance-related hyperinsulinemia, increased oxidative stress, and chronic inflammation, which are assumed to be the underlying causes of hepatocarcinogenesis in patients with diabetes. No appropriate surveillance methods for HCC development in patients with diabetes have been established, and liver diseases, including HCC, are often overlooked as complications of diabetes. Although some antidiabetic drugs are expected to prevent HCC development, further research on the optimal use of antidiabetic drugs aimed at hepatoprotection is warranted. Given the increasing medical and socioeconomic impact of diabetes on HCC development, diabetologists and hepatologists need to work together to develop strategies to address this emerging health issue. This article reviews the current knowledge on the impact of diabetes on the development and progression of HCC.
Publisher
Korean Association for the Study of the Liver,The Korean Association for the Study of the Liver
Subject
/ Carcinoma, Hepatocellular - diagnosis
/ Carcinoma, Hepatocellular - epidemiology
/ Carcinoma, Hepatocellular - etiology
/ Diabetes
/ Glucose
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Liver Neoplasms - complications
/ non-alcoholic fatty liver disease
/ Non-alcoholic Fatty Liver Disease - complications
/ Non-alcoholic Fatty Liver Disease - diagnosis
/ Non-alcoholic Fatty Liver Disease - epidemiology
/ Review
